Renub

    World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast

    Excel: 4 Hours
    PDF: 4 Hours
    Jan 2011
    Pages: 117

    Vaccine Industry - Market Overview
     
    For decades vaccines were a neglected corner of the drugs business, with old technology, little investment and abysmal profit margins. Many firms sold their vaccine divisions to concentrate on more profitable drugs. This troubled public-health experts because vaccines are a highly effective way of dealing with diseases. Happily, a renaissance is under way. World vaccine sales vaulted from US$ 10.1 Billion in 2005 to US$ 23 Billion in 2009. Insurers and governments in the rich world have started to pay higher prices: firms making new vaccines against pneumococcal disease or the human papilloma virus earning rich dividends. 
     
    As growth in sales of vaccines has became higher than the traditional business all major pharmaceutical companies are eyeing the vaccine market as driver for their growth. Many mergers and acquisition have taken place in this space as consolidation has become the keyword for future growth. With companies consolidating they can focus better in the market and keep their profit margins high. Recently, pharmaceutical company Pfizer acquired Wyeth, Merck acquired Schering Plough and Sanofi acquired Shantha Biotechnics. 
      
    Earlier biggest market of vaccines used to be basic pediatrics. But now more or less it’s losing its pre eminence due to expiry of patents on drugs and inclusion of basic pediatrics in basic healthcare provided by government at grass roots level. The growth in the vaccine industry is coming from the sectors like Pediatric Proprietary vaccine and Pediatric Enhanced Combination. According to our research findings Pediatric Proprietary vaccine was having 27% market in 2009 and it is expected to increase to 32% by 2015. Due to rising fear of terrorism Bio- Bio-protection vaccine future is also shinning. The Bio-protection vaccines market is expected to grow with a CAGR of 12.08% percent from 2009 to 2015. 
     
    Market for Meningitis vaccine and Rotavirus vaccine has crossed US$ 1 Billion by 2009. Seasonal flu vaccine market is forecasted to be more than US$ 7 Billion by 2016. Vaccines like Prevnar (Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to reach nearly US$ 3 Billion annual sales by 2009
     
    In terms of number of cases Measles, Mums, Rubella, Diphtheria, Pertussis and Tetanus cases have shown a decline continuously from 2001 till 2009. However, Yellow Fever is an exception to this whose number of cases has increased. Geographically US will continue to lead the vaccines market followed by Europe. Japanese vaccine market has also started to open up further from regulatory and political barriers. 
     
    Report Details
     
    World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast published by Renub Research talks about the vaccines market worldwide. This report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Pediatric Combinations & Booster, Pediatric Enhanced Combination, Pediatric Proprietary, Travel & Endemic Vaccines, Other Adults (HPV, Zoster etc), Bio-Protection. In this report , we have also describes different diseases, vaccines market size and cases worldwide such as Hepatitis B, Pneumococcal, Cervical Cancer, Malaria, Ebola, Tuberculosis (TB), Japanese Encephalitis, West Nile, Typhoid, Chlamydia, Gonorrhea etc. The report also covered different companies market share in vaccines segment. The report also forecast the sales of the key vaccines brands like Gardasil, Fluzone, Prevnar, Cervarix, Infanrix/Pediarix, Hepatitis (Engerix/Fendrix, Havrix, Twinrix).
     
    The report also focus on  major geograghical market such as US, Europe, Japan, India, China, their past, present, future  market. Major companies’ vaccines sales data for the year 2008 and 2009 are also there in the report. Major Acquisitions which were held in the past are also present in the report. The report has been researched at source globally and features latest available data covering:
     
    • Worldwide Vaccine Market past, present and future Scenario 
    • Six Vaccine Market-By Sector depth Insight of past, present and future market
    • Nineteen diseases vaccines market size
    • Nineteen diseases; cases available worldwide are covered up 
    • Fourteen companies market share in vaccines segment are covered up
    • Three major companies vaccines sales in 2008 and 2009
    • Major geographical market such as US, Europe, Japan, China, India depth insight of past, present, future market
    • Blockbuster vaccines depth insight past, present and future market
    • Major acquisition in vaccines sector
     
    Research Highlights
     

    • 7 vaccine sectors have been analyzed in this report (for details refer figure no. 4 below in Table of Contents)
    • World vaccines market will cross the mark of US$ 40 Billion by 2015
    • Pediatric proprietary vaccine market is the biggest vaccine sector with more than US$ 6 Billion market in 2009
    • In 2009 four companies (GSK, Sanofi-Aventis, Wyeth and Merck & Co.) together controls 71% of the vaccines market worldwide 
    Influenza vaccine market is expected to cross US$ 7 Billion market by 2015  
    • Bio-protection and Travel & Endemic vaccines market is expected to double by 2015 from their market in 2009 
    • US is the biggest vaccine market worldwide with more than US$ 10 Billion and its expected to lead the market till 2015
    • Europe vaccine market is the second biggest market after US
    • By June 2010 Europe experienced 350% rise in polio cases compared to 2009  
    • Japanese encephalitis cases has shown a decline of 12% in 2009 compared to 2008 
    • Malaria vaccine market for public is expected to cross US$ 400 Million by 2025
    • Cervical Cancer vaccine market is forecasted to cross US$ 4 Billion mark by 2012 and there after its year on year growth will slowdown
    • Prevner a Pfizer a product is expected to become the first vaccine to cross US$ 5 Billion mark by 2015
    • 19 vaccines have been analyzed in the report (for details refer heading no. 6 below in Table of Contents)
     
    Data Sources 
     

    Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations. 

    1. Executive Summary
     
    2. Vaccines Market – An Attraction for Pharmaceuticals Companies

    2.1 Pharmaceuticals Companies Increasing Revenue from Vaccines Segment
    2.2 To Makeup the Lost time Pharmaceutical Companies going for Major Acquisitions
    2.3 Several New Vaccines, Many with Blockbuster Potential
     
    3. Worldwide Vaccines Market & Future Forecast
    3.1 World (By Segments) – Vaccines Market Share & Future Forecast
    3.2 World Vaccine Companies Market Share (2009) 
     
    4. By Segments – Vaccines Market & Future Forecast till 2015
    4.1 Pediatric Combinations & Boosters Vaccines
    4.2 Pediatric-Enhanced Combinations Vaccines
    4.3 Pediatric-Proprietary (Pneumococcal, Rotavirus, Meningitis) Vaccines
    4.4 Influenza Vaccines
    4.5 Travel & Endemic Vaccines
    4.6 Other Adults (HPV, Zoster, HAI, etc) Vaccines
    4.7 Bio Protection Vaccines
     
    5. Major Geographic Vaccines Market
    5.1 United States Vaccines Market & Future Forecast
    5.2 Europe Vaccines Market & Future Forecast
    5.3 Japan Vaccines Market & Future Forecast
    5.4 India Vaccines Market & Future Forecast
    5.5 China Vaccines Market & Future Forecast
     
    6. Major Vaccine Cases, Present & Future Market
    6.1 Pneumococcal Vaccines (in 2000) 
    6.1.1 Pneumococcal Cases
    6.1.2 Market Size of Pneumococcal Vaccines & Future Forecast
    6.2 Tuberculosis (TB) Vaccines
    6.2.1 Number of Tuberculosis Cases
    6.2.2 Market Size of Tuberculosis Vaccines & Future Forecast
    6.3 Measles, Mumps & Rubella (MMR) Vaccines
    6.3.1 Number of Measles, Mumps & Rubella Cases
    6.3.2 Market Size of Measles & Rubella Vaccine
    6.4 Seasonal Flu Vaccines
    6.4.1 Number of Seasonal Flu Vaccine Doses
    6.4.2 Market Size of Seasonal Flu Vaccine & Future Forecast
    6.5 DTP Vaccines
    6.5.1 Number of Diphtheria, Pertussis and Tetanus Cases
    6.6 Yellow Fever Vaccines
    6.6.1 Number of Yellow Fever Cases
    6.7 Chlamydia Vaccines
    6.7.1 Number of Chlamydia Cases (in 1995 & 1999) 
    6.7.2 Chlamydia Vaccines Market (in 2012) & Funding
    6.8 Gonorrhea Vaccines
    6.8.1 Number of Gonorrhea Cases (in 1995 & 1999) 
    6.9 Colorectal Cancer Vaccines
    6.9.1 Number of Colorectal Cancer Cases
    6.9.2 Market Size of Colorectal Cancer (in 2012) 
    6.10 Polio Vaccines
    6.10.1 Number of Polio Cases
    6.10.2 Market Size of Polio Vaccines & Future Forecast
    6.11 Meningitis Vaccines
    6.11.1 Number of Meningitis Cases
    6.11.2 Market Size of Meningitis Vaccine & Future Forecast
    6.12 Rotavirus Vaccines
    6.12.1 Number of Rotavirus Cases
    6.12.2 Market Size of Rotavirus Vaccines & Future Forecast
    6.13 Japanese Encephalitis Vaccines
    6.13.1 Number of Japanese Encephalitis Cases
    6.13.2 Market Size of Japanese Encephalitis & Future Forecast
    6.14 Hepatitis B Vaccines
    6.14.1 Hepatitis B Immunization Coverage
    6.14.2 Market Size of Hepatitis B Vaccine
    6.15 Malaria Vaccines
    6.15.1 Number of Malaria Cases
    6.15.2 Market Size of Malaria Vaccine & Future Forecast
    6.16 West Nile Vaccines
    6.16.1 Number of West Nile Cases (in USA, 1999 to 2005) 
    6.16.2 Market Size of West Nile Vaccine & Future Forecast
    6.17 Ebola Vaccines
    6.17.1 Number of Ebola Cases
    6.17.2 Market Size of Ebola Vaccines & Future Forecast
    6.18 Cervical Cancer Vaccines
    6.18.1 Number of Cervical Cancer Cases
    6.18.2 Market Size of Cervical Cancer Vaccine & Future Forecast
    6.19 Typhoid Vaccines
    6.19.1 Number of Typhoid Cases (in 2000) 
    6.19.2 Market Size of Typhoid Vaccines (in 2003) & Future Forecast (in 2014) 
     
    7. Blockbuster Vaccines Forecast
    7.1 Fluzone Vaccine Market & Forecast
    7.2 Prevnar Vaccine Market & Forecast
    7.3 Gardasil Vaccine Market & Forecast
    7.4 Cervarix Vaccine Market & Forecast
    7.5 Infanrix, Pediarix Vaccine Market & Forecast
    7.6 Hepatitis (Engerix/Fendrix, Havrix, Twinrix) Vaccine Market & Forecast

     

    List of Figures:
     
    Figure 2 1: Worldwide – Vaccine Companies (GSK, Merck & Co., Novartis & Sanofi-Aventis) – Sales as a Percentage of Overall Pharmaceutical Sales (Percent), 2006
    Figure 3 1: Worldwide – Vaccines Market (Million US$), 2005 – 2009
    Figure 3 2: Worldwide – Future Forecast for Vaccines Market (Million US$), 2010 - 2015
    Figure 3 3: Worldwide (By Segment) – Vaccines Market Share (Percent), 2005 – 2009
    Figure 3 4: Worldwide (By Segment) – Forecast for Vaccines Market Share (Percent), 2010 – 2014
    Figure 3 5: Worldwide – Vaccine Companies Market Share (Solvay, Baxter, CSL, Crucell, Novartis, Wyeth, GSK, Merck & Co. Sanofi Pasture MDS-Merck & Co Share, Sanofi Pasture MSD-Sanofi Share, Sanofi & AZN), (Percent), 2009
    Figure 4 1: Worldwide – Pediatric Combinations & Boosters Vaccines Market (Million US$) 2005 – 2009
    Figure 4 2: Worldwide – Future Forecast for Pediatric Combinations & Boosters Vaccines Market (Million US$), 2010 – 2015
    Figure 4 3: Worldwide – Pediatric Enhanced Combinations Vaccine Market (Million US$) 2005 – 2009
    Figure 4 4: Worldwide – Future Forecast for Pediatric Enhanced Combinations Vaccines Market (Million US$), 2010 – 2015
    Figure 4 5: Worldwide – Pediatric-Proprietary Vaccines Market (Million US$), 2005 – 2009
    Figure 4 6: Worldwide – Future Forecast for Pediatric-Proprietary Vaccines Market (Million US$), 2010 – 2015
    Figure 4 7: Worldwide – Influenza Vaccines Market (Million US$), 2005 – 2009
    Figure 4 8: Worldwide – Future Forecast for Influenza Vaccines Market (Million US$), 2009 – 2014
    Figure 4 9: Worldwide – Travel & Endemic Vaccines Market (Million US$), 2005 – 2009
    Figure 4 10: Worldwide – Future Forecast for Travel & Endemic Vaccines Market (Million US$), 2010 – 2015
    Figure 4 11: Worldwide – Other Adults (HPV, Zoster, HAI, etc) Vaccines Market (Million US$), 2005 – 2009
    Figure 4 12: Worldwide – Future Forecast for Other Adults (HPV, Zoster, HAI, etc) Vaccines Market (Million US$), 2010 – 2015
    Figure 4 13: Worldwide – Bio-Protection Vaccines Market & Future Forecast (Million US$), 2010 – 2015
    Figure 5 1: US – Vaccines Market (Million US$), 2005 – 2009
    Figure 5 2: US – Future Forecast for Vaccines Market (Million US$), 2010 – 2013
    Figure 5 3: Europe – Vaccines Market (Million US$), 2005 – 2009
    Figure 5 4: Europe – Future Forecast for Vaccines Market (Million US$), 2010 – 2013
    Figure 5 5: Japan – Vaccines Market (Million US$), 2005 – 2009
    Figure 5 6: Japan – Future Forecast for Vaccines Market (Million US$), 2010 – 2013
    Figure 5 7: India – Vaccines Market (Million US$), 2005 – 2009
    Figure 5 8: India – Future Forecast for Vaccines Market (Million US$), 2010 – 2013
    Figure 5 9: China – Vaccines Market (Million US$), 2005 – 2009
    Figure 5 10: China – Future Forecast for Vaccines Market (Million US$), 2010 – 2013
    Figure 6 1: Worldwide – Pneumococcal Vaccine Pipeline
    Figure 6 2: Worldwide – Pneumococcal Vaccine Market (Billion US$), 2004 – 2009
    Figure 6 3: Worldwide – Forecast for Pneumococcal Vaccine Market (Billion US$), 2012 & 2018
    Figure 6 4: Worldwide – Forecast for Global Funds for Immunization in Pneumococcal Vaccine Market (Billion US$ & Percent), 2018
    Figure 6 5: Worldwide – By Geographic Region Number of Tuberculosis Cases (Thousand), 2006 & 2007
    Figure 6 6: Worldwide – Distribution of Tuberculosis Patients in Previous Cases, New Smear-positive Cases & HIV-positive Cases (Million & Percent), 2006
    Figure 6 7: Worldwide – Forecast for Tuberculosis (TB) BCG-Replacement Vaccine (Million US$), 2013 – 2030
    Figure 6 8: Worldwide – Forecast for Tuberculosis (TB) Booster Vaccine (Million US$), 2013 – 2030
    Figure 6 9: Worldwide – Forecast for Tuberculosis (TB) Prime-Boost Strategy (Million US$), 2013 – 2030
    Figure 6 10: Worldwide – Market & Sales Growth of Measles, Rubella Vaccine (Million US$ & %), 2006 & 2007
    Figure 6 11: Worldwide – Seasonal Influenza Vaccines Demand (Million Doses) 1997 – 2009
    Figure 6 12: Worldwide – Future Forecast for Seasonal Influenza Vaccines Demand (Million Doses) 2010 – 2016
    Figure 6 13: Worldwide – Seasonal Flu Market (Million US$) 1997 – 2009
    Figure 6 14: Worldwide – Future Forecast for Seasonal Flu Market 2010 – 2016
    Figure 6 15: Worldwide – Number of Chlamydia Cases (Million), 1995 & 1999
    Figure 6 16: USA – Number of Chlamydia Cases (Number), 2002 & 2007
    Figure 6 17: Worldwide – Number of Gonorrhea cases (Million), 1995 & 1999
    Figure 6 18: USA – Number of Gonorrhea Cases (Number), 1997, 2000 – 2008
    Figure 6 19: Worldwide – Number of Clorectal Cancer Cases (Number), 1975, 2000, 2003, 2007
    Figure 6 20: Worldwide – Polio/Pertussis/Hib   Vaccine Market (Million US$) 2008 – 2009
    Figure 6 21: Worldwide – Forecast for Polio/Pertussis/Hib Vaccine Market (Million US$) 2010 – 2014
    Figure 6 22: Worldwide – Number of Meningitis Cases (Number), 2001 – 2009
    Figure 6 23: Worldwide – Meningitis Vaccine Market (Billion US$), 2004, 2009, 2017
    Figure 6 24: Worldwide – Rotavirus Vaccine Market (Million US$), 2006 – 2009
    Figure 6 25: Worldwide – Forecast for Rotavirus Vaccine Market (Million US$), 2010 – 2014
    Figure 6 26: Worldwide – Japanese Encephalitis Vaccine Market (Million US$), 2004 – 2009
    Figure 6 27: Worldwide – Forecast for Japanese Encephalitis Vaccine Market (Million US$), 2010 – 2014
    Figure 6 28: Worldwide – Hepatitis B Vaccine Market (Billion US$), 2005 – 2010
    Figure 6 29: Worldwide – Combined Hepatitis B Vaccine Market of Europe & Asia Pacific Region (US$ Billion & Percent), 2006
    Figure 6 30: Worldwide – Forecast for Malaria Vaccine Market (Million US$), 2010 – 2025
    Figure 6 31: Worldwide – Forecast for Military Market for Malaria Vaccine (Million US$), 2010 – 2025
    Figure 6 32: Worldwide – Forecast for Private Market for Malaria Vaccine (Million US$), 2010 – 2025
    Figure 6 33: Worldwide – Forecast for Public Market for Malaria Vaccine (Million US$), 2010 – 2025
    Figure 6 34: US – Number of West Nile Virus Cases (Number), 1999 – 2005
    Figure 6 35: Worldwide – Forecast for West Nile Vaccines Market (Million US$), 2010
    Figure 6 36: Worldwide – Forecast for West Nile Vaccines Market (Million US$), 2010
    Figure 6 37: Worldwide – Number of Cervical Cancer Cases & Deaths (Number), 2000, 2002, 2007
    Figure 6 38: Worldwide – Forecast for Cervical Cancer Deaths (Number), 2015 & 2030
    Figure 6 39: Worldwide – Cervical Cancer Vaccines Market (Million US$), 2007 – 2009
    Figure 6 40: Worldwide – Forecast for Cervical Cancer Vaccine Market (Million US$), 2010 – 2014
    Figure 6 41: Worldwide – Travelers Market for Typhoid Vaccine (Million US$), 2003 & 2014
    Figure 7 1: Worldwide – Fluzone Vaccine Market (Million US$) 2007 – 2009, 2012
    Figure 7 2: Worldwide – Prevnar Vaccine Market (Million US$) 2000 – 2009
    Figure 7 3: Worldwide – Forecast for Prevnar Vaccine Market (Million US$) 2010 – 2015
    Figure 7 4: Worldwide – Gardasil Vaccine Market (Million US$) 2006 – 2009
    Figure 7 5: Worldwide – Forecast for Gardasil Vaccine Market (Million US$) 2010 – 2014
    Figure 7 6: Worldwide – Cervarix Vaccine Market (Million US$) 2007 – 2009
    Figure 7 7: Worldwide – Forecast for Cervarix Vaccine Market (Million US$) 2010 – 2014
    Figure 7 8: Worldwide – Infanrix/Pediarix Vaccine Market (Million US$) 2004 – 2009
    Figure 7 9: Worldwide – Forecast for Infanrix/Pediarix Vaccine Market (Million US$) 2010 – 2014
    Figure 7 10: Worldwide – Hepatitis (Engerix/Fendrix, Havrix, Twinrix) Vaccine Market (Million US$) 2004 – 2009
    Figure 7 11: Worldwide – Forecast for Hepatitis (Engerix/Fendrix, Havrix, Twinrix) Vaccine Market (Million US$) 2010 – 2014
     

    List of Tables:
     
    Table 2 1: Worldwide – Vaccine Sales of Companies: Merck, GSK, Sanofi Aventis (Million US$) 2008 & 2009
    Table 2 2: Worldwide – 15 Major Acquisitions in Pharmaceuticals (Billion US$), 2005 – 2009
    Table 2 3: Worldwide – 16 Major Acquisitions in Biotechnology (Billion US$), 2005 – 2009
    Table 2 4: Recent Main Acquisitions in Vaccines Industry (Million) 2001 -2009
    Table 2 5: Worldwide – Vaccines Market (Prevnar, Gardasil, Engerix-B, Havrix, Twinrix, Infanrix, Pediarix, Fluzone, and IPOL, Hib, Petrussis) – Sales (Billion US$), 2006 - 2008
    Table 6 1: Worldwide – Number of Pneumococcal Cases, 2000
    Table 6 2: Worldwide (By Geographic Region) – Number of Measles Cases (Number), 2001 – 2009
    Table 6 3: Worldwide (By Geographic Region) – Number of Mumps Cases (Number), 2001 – 2009
    Table 6 4: Worldwide (By Geographic Region) – Number of Rubella cases (Number), 2001 – 2009
    Table 6 5: Worldwide (By Geographic Region) – Number of Diphtheria Cases (Number), 2001 – 2009
    Table 6 6: Worldwide (By Geographic Region) – Number of Pertussis Cases (Number), 2001 – 2009
    Table 6 7: Worldwide (By Geographic Region) – Number of nTetanus Cases (Number), 2001 – 2009
    Table 6 8: Worldwide (By Geographic Region) – Number of tTetanus Cases (Number), 2001 – 2009
    Table 6 9: Worldwide (By Geographic Region) – Number of Yellow Fever Cases (Thousand), 2001 – 2009
    Table 6 10: Worldwide – Chlamydia Vaccines Market (Billion US$), 2012
    Table 6 11: Worldwide – Grant Received from Pharmaceutical Companies
    Table 6 12: Worldwide – Colorectal Cancer Market (Billion US$), 2012
    Table 6 13: Worldwide (By Geographic Region) – Number of Polio Cases (Number), 2001 – 2009, till June 2010
    Table 6 14: Worldwide – Top 42 Countries with Maximum Number of Polio Cases (Number), 2000 – 2008, till March 2009
    Table 6 15: Worldwide – 27 Countries with Number of Diarrhea Hospitalizations Cases and Rotavirus Cases (Number & Percent), 2000 – 2004
    Table 6 16: Worldwide – Total number of patients aged <5 years who were tested for acutegastroenteritis and medium detection rate of rotavirus by WHO Region, 2001 – 2008
    Table 6 17: Worldwide – By Geographic Region Number of Japanese Encephalitis Cases (Number), 2006 – 2009
    Table 6 18: Worldwide (By Region) – Hepatitis B Vaccine Immunization Coverage (Percent), 2007 –2008
    Table 6 19: Worldwide (By Geographic Region) – Number of Malaria Cases (Numbers), 2004 – 2008
    Table 6 20: Worldwide – Number of Ebola Cases & Deaths (Numbers), 1976 – 2008
    Table 6 21: Worldwide – Number of Typhoid Cases (Number), 2000

    Related Reports

    • Influenza Vaccines Market & Forecast - Worldwide Analysis

      The Influenza vaccines market represent an attractive market characterize by sturdy growth prospects. Increasing awareness, growing vaccination coverage in the emerging countries, rising government support for immunization against Seasonal Influenza and increased focus on the production of treatments for vulnerable populations by introducing new vaccines and vaccines with a better route of administration are the main drivers to galvanized Influenza vaccines market. ...

      Price: $1,490.00